Introduction
============

Inherited optic atrophy (OA) is characterized by the degeneration of retinal ganglion cells (RGCs) and other neuronal populations, which results in thinning of the retinal nerve fiber layer (RNFL) \[[@r1]\]. Typical clinical features of OA include progressive loss of bilateral vision (usually occurs within the first decade), central or paracentral scotomas, tritanopia, and pallor of the optic discs \[[@r1]-[@r3]\]. Familial history, temporal or diffuse pallor of the optic discs disclosed by eye fundus, and a reduced amplitude of the waveform detected by visually evoked potentials (VEP) may contribute to the clinical diagnosis of OA \[[@r2]\]. According to the inheritance pattern, OA can be categorized into autosomal dominant optic atrophy (ADOA) and mitochondrial inherited Leber hereditary optic neuropathy (LHON). ADOA, showing a worldwide prevalence of 1:50,000, is the most common form of inherited optic neuropathy \[[@r3]\].

ADOA shows genetic heterogeneity \[[@r2],[@r4]\]. To date, two genes, optic atrophy 1 (*OPA1*, OMIM\_[605290](https://www.ncbi.nlm.nih.gov/omim/?term=605290)) and *OPA3* (OMIM\_[606580](https://www.ncbi.nlm.nih.gov/omim/?term=606580)), and three loci, *OPA4* (OMIM \_[605293](https://www.ncbi.nlm.nih.gov/omim/?term=605293)), *OPA5* (OMIM \_[610708](https://www.ncbi.nlm.nih.gov/omim/?term=610708)), and *OPA8* (OMIM\_[616648](https://www.ncbi.nlm.nih.gov/omim/?term=616648)), are reported to be correlated with ADOA. Among all, *OPA1* is the most common causative gene for ADOA \[[@r5]\]. *OPA1* consists of 31 coding exons, and it encodes dynamin-like guanosine triphosphates (GTPase) localized to the mitochondria. Protein encoded by *OPA1* targets the external face of the mitochondrial inner membrane, controls the structural integrity of mitochondrial cristae, and keeps their junctions tight during apoptosis \[[@r6]\]. To date, over 400 variants in *OPA1* have been identified ([mitodyn](http://mitodyn.org/home.php?select_db=OPA1)). About 20% of all identified variants associate with the "ADOA plus" syndrome \[[@r7],[@r8]\]. Patients with "ADOA plus" syndrome present OA in childhood, followed by the subsequent onset of chronic progressive external ophthalmoplegia (PEO), ptosis, sensorineural deafness, peripheral neuropathy, and myopathy in adult life \[[@r9]\]. Most reported *OPA1* mutations are missense mutations located in the GTPase domain and dynamin central region, which interrupt the protein function \[[@r2],[@r10]\].

Next-generation sequencing (NGS), an approach that enables sequencing of a panel of candidate genes, has been revealed as an efficient tool for the molecular diagnosis of inherited retinal dystrophies (IRDs) \[[@r2],[@r10]\]. Because no effective clinical therapy has been developed for OA, NGS-based molecular diagnosis will not only help to improve its clinical diagnosis, but is also essential for its prenatal diagnosis. Herein, by means of a targeted NGS approach, we reveal novel *OPA1* mutations in 15 Chinese families with OA.

Methods
=======

Participants and clinical investigations
----------------------------------------

Our study complied with the Declaration of Helsinki, and it was approved and prospectively reviewed by the ethics committee of the First Affiliated Hospital of Nanjing Medical University (2017-SRFA-034). Written informed consent was obtained from all participants or their legal guardians before enrollment. All participants underwent routine ophthalmic examinations, including best-corrected visual acuity (BCVA), funduscopy, slit-lamp examination, and fundus photography. The VEP test was selectively performed on patients OA02-II:1, OA08-II:1, and OA12-II:1. Another 150 unrelated Chinese controls were also included, each of whom received basic ophthalmic examinations to exclude major ocular problems. Peripheral blood samples from all participants were collected in EDTA tubes. DNA extraction from leukocytes was performed using a RelaxGene Blood DNA System (Qiagen, Valencia, CA) per the manufacturer's protocols.

Targeted gene capture, NGS, bioinformatics analyses, and Sanger sequencing
--------------------------------------------------------------------------

Targeted sequence capture microarrays that could capture the coding and exon-intronic boundary regions of all known retinal disease genes were used in this study. Details of the targeted genes of the commercial array have been previously described \[[@r11]-[@r13]\]. Sequence capture, enrichment, elution, and NGS were conducted in cooperation with BGI-Shenzhen or MyGenostics-Beijing, as previously stated \[[@r14],[@r15]\].

All detected variants were further filtered against the following six single nucleotide polymorphism (SNP) databases, including the [dbSNP144](file:///C:\\\\Users\\\\user\\\\AppData\\\\Local\\\\Temp\\\\(http:\\\\hgdownload.cse.ucsc.edu\\\\goldenPath\\\\hg19\\\\database\\\\snp144.txt.gz), [HapMap](ftp://ftp.ncbi.nlm.nih.gov/hapmap) project, [1000 Genome Project](ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp), [YH database](http://yh.genomics.org.cn/), [Exon Variant Server](http://evs.gs.washington.edu/EVS/), and [ExAC](http://exac.broadinstitute.org/) databases. Variants with a minor allele frequency value of over 0.001 were discarded. Sanger sequencing was subsequently performed for a mutation validation, intrafamilial genotype--phenotype cosegregation analysis, and prevalence test in 150 controls. Information of primers are listed in Appendix 1.

In-silico analyses
------------------

Evolutionary conservation of the mutated amino acids was analyzed through the alignment of OPA1 orthologous protein sequences from the following species: *Homo sapiens* (ENSP00000354681), *Pan troglodytes* (ENSPTRP00000027094), *Bos taurus* (ENSBTAP00000026013), *Mus musculus* (ENSRNOP00000002338), *Gallus gallus* (ENSGALP00000042204), *Danio rerio* (ENSDARP00000095031), *Drosophila melanogaster* (FBpp0086700), and *Caenorhabditis elegans* (D2013.5). Online predictive software, including [SIFT](http://sift.jcvi.org/) \[[@r16]\], [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/) \[[@r17]\], and [PROVEN](http://provean.jcvi.org/index.php) \[[@r18]\], was applied to evaluate the potential pathogenicity of identified mutations. The Splicing Regulation Online Graphical Engine ([SROOGLE](http://sroogle.tau.ac.il/)) online prediction software was used to determine whether splice site variations would alter the regular splicing sites.

Results
=======

Clinical manifestations
-----------------------

Family pedigrees are shown in [Figure 1](#f1){ref-type="fig"}. All included patients presented typical OA symptoms, and their detailed clinical data are summarized in [Table 1](#t1){ref-type="table"}. Briefly, the onset ages varied from infant to 12 years old. Patient OA02-II:2 had vision defects since infancy, while patients from families OA06 and OA11 were completely unaffected until 10 to 12 years old. Most patients reported having bilateral visual impairments since their first decade of life, which was consistent with previous reports. The disease progression also varied. For example, patients OA06-I:1 and OA11-II:1 shared a similar age and onset age. However, the BCVAs for patient OA06-I:1 are 0.5 OD and 0.4 OS, while patient OA11-II:1 had much poorer visual conditions (0.1 OU). Rapid disease progression was also noticed in patient OA02-II:2. She also presented with asymmetric visual defects, with her BCVAs being 0.25 OD and 0.02 OS. Most patients had a relatively slow and stable disease progression. Nystagmus was noticed in all three patients from family OA01. Fundus presentations of all patients demonstrated bilateral optic nerve pallor ([Figure 2](#f2){ref-type="fig"}). VEP results were attainable in five patients, including OA02-II:2, OA08-I:1, OA08-II:1, OA12-I:1, and OA12-II:1. All patients showed bilateral diminished VEP presentations. None of the patients presented systemic abnormalities.

![Family pedigrees. The sex (male, square; female, circle), phenotype (unaffected, empty symbol; clinically affected, black-filled symbol), and genotype (unaffected, +/+; genetically affected, MU/+) of all recruited members are shown. Probands are indicated by arrows.](mv-v25-912-f1){#f1}

###### Clinical features of recruited patients.

  **Patient ID**   **Age (years) /Sex**   **Onset Age (years)**   **BCVA (logMAR)**   **Optic disc**   **VEP**   
  ---------------- ---------------------- ----------------------- ------------------- ---------------- --------- ------------
  OA01-II:3        60/F                   3                       0.02                0.01             Pale      NA
  OA01-III:1       38/M                   8                       0.1                 0.1              Pale      NA
  OA01-IV:1        16/F                   5                       0.05                0.05             Pale      NA
  OA02-II:2        30/F                   Infant                  0.25                0.02             Pale      Diminished
  OA03-II:1        8/M                    3                       0.2                 0.3              Pale      NA
  OA04-II:2        10/M                   6                       0.5                 0.5              Pale      NA
  OA05-II:1        10/M                   6                       0.4                 0.5              Pale      NA
  OA06-I:1         42/M                   12                      0.5                 0.4              Pale      NA
  OA06-II:1        14/F                   11                      0.2                 0.1              Pale      NA
  OA07-II:2        9/M                    4                       0.4                 0.3              Pale      NA
  OA08-I:1         32/M                   8                       0.3                 0.3              Pale      Diminished
  OA08-II:1        9/M                    5                       0.5                 0.4              Pale      Diminished
  OA09-II:1        8/M                    5                       0.1                 0.1              Pale      NA
  OA10-II:2        9/M                    7                       0.2                 0.2              Pale      NA
  OA11-II:1        43/F                   12                      0.1                 0.1              Pale      NA
  OA11-II:2        42/F                   10                      0.1                 0.1              Pale      NA
  OA12-I:1         30/M                   8                       0.3                 0.3              Pale      Diminished
  OA12-II:1        6/M                    4                       0.3                 0.3              Pale      Diminished
  OA13-I:2         31/F                   6                       0.4                 0.4              Pale      NA
  OA13-II:1        7/M                    4                       0.3                 0.3              Pale      NA
  OA14-I:2         28/F                   6                       0.3                 0.4              Pale      NA
  OA14-II:1        6/M                    3                       0.25                0.3              Pale      NA
  OA15-II:1        14/M                   6                       0.2                 0.2              Pale      NA

**Abbreviations:** OD: right eye; OS: left eye; F: female; M: male; BCVA: best corrected visual acuity; VEP: visual evoked potential; NA: not available.

![Fundus presentations. **A-O**: Fundus photographs of all probands demonstrate bilateral optic nerve head pallor.](mv-v25-912-f2){#f2}

Genetic investigation
---------------------

Probands from all 15 families were selected for NGS, as mentioned before. After a comprehensive genetic analysis, 14 heterozygous mutations in total in the *OPA1* gene ([NM_130837](https://www.ncbi.nlm.nih.gov/nuccore/NM_130837)) were identified as potentially disease causing in the 15 families, including eight novel variants and six recurrent mutations ([Figure 3](#f3){ref-type="fig"} and [Table 2](#t2){ref-type="table"}). Eleven of the 14 mutations were located in the GTPase domain and dynamin central region ([Figure 4A](#f4){ref-type="fig"}). All identified variants segregated the disease phenotypes in corresponding families and were absent in 150 unrelated normal controls.

![Chromatograms of wild-type (top) and mutant (bottom) *OPA1* sequences in all recruited families.](mv-v25-912-f3){#f3}

###### Characteristics of identified *OPA1* mutations.

  **Family ID**   **Mutation**     **Exon**       **Bioinformatics Analysis**   **Reported** **/Novel**   **MAF**                                                       
  --------------- ---------------- -------------- ----------------------------- ------------------------- --------- ------------ ------------ ------------ ------------ ----------
  OA01            c.968A\>G        p.Y323C        missense                      Het                       E10       DA (0.000)   PD (1.000)   DE (−8.03)   Novel        \-
  OA02            c.193C\>G        p.L65V         missense                      Het                       E2        DA (0.016)   B (0.278)    N (−0.63)    Novel        \-
  OA03            c.1499G\>A       p.R500H        missense                      Het                       E16       DA (0.001)   PD (1.000)   DE (−4.70)   CM030379     \-
  OA04            c.1800C\>A       p.S600R        missense                      Het                       E19       DA (0.001)   PD (1.000)   DE (−4.64)   CM061154     \-
  OA05            c.1071dupT       p.T358\*       nonsense                      Het                       E11       \-           \-           \-           Novel        \-
  OA06            c.1034G\>A       p.R345Q        missense                      Het                       E10       DA (0.041)   PD (0.978)   DE (−3.50)   CM002636     \-
  OA07            c.987_988del     p.S331\*       nonsense                      Het                       E10       \-                        \-           Novel        \-
  OA08            c.2012+2T\>G     \-             splice site                   Het                       E22--23   \-                        \-           Novel        \-
  OA09            c.2873_2876del   p.V958Gfs\*2   frameshift                    Het                       E29       \-                        \-           \[[@r26]\]   4/121408
  OA10            c.1499G\>A       p.R500H        missense                      Het                       E16       DA (0.001)   PD (1.000)   DE (−4.70)   CM030379     \-
  OA11            c.112C\>T        p.R38\*        nonsense                      Het                       E2        \-           \-           \-           CM024785     \-
  OA12            c.1036--1G\>C    \-             splice site                   Het                       E10--11   \-           \-           \-           Novel        \-
  OA13            c.2126A\>G       p.D709G        missense                      Het                       E22       DA (0.001)   PD (1.000)   DE (−6.72)   Novel        \-
  OA14            c.804_805del     p.K269Nfs\*1   frameshift                    Het                       E8        \-           \-           \-           \[[@r27]\]   \-
  OA15            c.1036_1038del   p.V346del      deletion                      Het                       E11       \-           \-           \-           Novel        \-

Abbreviations: Het: heterozygous; DA: damaging; PD: probably damaging; B: benign; DE: deleterious; N: neutral; MAF: minor allele frequency.

![Diagrammatic representation and conservational analyses. **A**: Diagrammatic representation of the 14 identified mutations in the context of genome structure (upper) and eight isoforms of the OPA1 protein (below), derived from the alternative splicing of exons 4, 4b, 5, and 5b. The OPA1 protein includes a mitochondria-targeting sequence (MTS), a GTPase domain, a middle domain, and a C-terminus GTPase effector domain (GED). **B**: Orthologous protein sequence alignment of OPA1 from human (*H. sapiens*), chimpanzees (*P. troglodytes*), cows (*B. taurus*), rats (*M. musculus*), chickens (*G. gallus*), zebrafish (*D. rerio*), fruit flies (*D. melanogaster*), and roundworms (*C. elegans*).](mv-v25-912-f4){#f4}

The eight novel variations comprised three missense mutations (c.193C\>G in family OA02, c.968A\>G in family OA01, and c.2126A\>G in family OA13), one deletion (c.1036_1038del in family OA15), two nonsense mutations (c.987_988del in family OA07 and c.1071dupT in family OA05), and two splice site mutations (c.1036--1G\>C in family OA12, and c.2012+2T\>G in family OA08; [Figure 1](#f1){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}, and [Table 2](#t2){ref-type="table"}). The novel missense variant c.968A\>G, leading to the amino acid change from tyrosine to cysteine at residue 323 (p.Y323C), was located within the GTPase domain of the OPA1 protein ([NP_570850](https://www.ncbi.nlm.nih.gov/nuccore/NP_570850); [Figure 4A](#f4){ref-type="fig"}). A conservational analysis indicated that residue Tyr323 in OPA1 was evolutionarily conserved among multiple species ([Figure 4B](#f4){ref-type="fig"}). Potential deleterious effects of this mutation was implied by all three types of online predicting software, including PROVEN (−8.03, deleterious), SIFT (0.000, damaging), and Polyphen-2 (1.000, probably damaging; [Table 2](#t2){ref-type="table"}). Another variant c.193C\>G, causing substitution from leucine to valine at conserved residue 65 (p.L65V), was located in the basic domain of the OPA1 protein ([Figure 4A,B](#f4){ref-type="fig"}). This variation was predicted to be damaging (0.016) by the SIFT online predicting software ([Table 2](#t2){ref-type="table"}). The other missense mutation, c.2126A\>G, leading to the transformation from aspartic acid to glycine at residue 709 (p.D709G), was located in the dynamin central domain of the OPA1 protein ([Figure 4A](#f4){ref-type="fig"}). Residue Asp709 was also highly conserved among all tested species ([Figure 4B](#f4){ref-type="fig"}). The potential deleterious effects of the mutation were revealed by [PROVEAN](file:///C:\\\\Users\\\\gagiima\\\\Dropbox\\\\molvis\\\\v25\\\\a83\\\\912\\\\provean.jcvi.org\\\\index.php) (−6.72, deleterious), SIFT (0.001, damaging), and Polyphen-2 (1.000, probably damaging).

We next used the [SROOGLE](http://sroogle.tau.ac.il/) online prediction software to determine whether the two splice site variations would cause abolishment of the regular splicing sites. According to our data, mutation c.1036--1G\>C was found to remarkably decrease the splice site score from 4.81 to −3.26 in the Max entropy model and from 81.06 to 57.62 in the PSSM model. The regular splice site was found completely abolished by mutation c.2012+2T\>G. The nonsense mutations c.987_988del and c.1071dupT would introduce immediate translation stop codons at residues 331 and 358, respectively, thus generating a truncated protein or causing nonsense-mediated mRNA decay (NMD).

Discussion
==========

Herein, we report the identification of 14 heterozygous *OPA1* variants in 15 Chinese OA families, including eight novel and six recurrent mutations. All included patients show typical OA presentation. Some of the literature suggests that gender might contribute to the severity of OA caused by an *OPA1* mutation \[[@r19]\]. However, our data do not reveal such a correlation. The average onset age of female patients ranged from infant to 12 years old (average: 6.63 years old), and the average onset age of male patients ranged from 3 to 12 years old (average: 5.93 years old). The OA progression shows no notable difference between males and females. Of all included patients, 15 are male and eight are female. The greater number of male patients in this study is probably due to the *de novo OPA1* mutations in families OA07, OA09, OA10, and OA15.

The OPA1 protein plays an important role in maintaining the mitochondrial structure and inhibiting apoptosis. The N-terminal mitochondrial localization signal sequence of OPA1 can direct protein into the mitochondria. Recent studies indicate that OPA1 proteins accumulate in the mitochondrial inner membrane and serve as anchors for mitochondrial DNA (mtDNA), contributing to its replication and distribution \[[@r20],[@r21]\]. OPA1 insufficiency could disrupt oxidative phosphorylation, disturb mtDNA maintenance and replication, and further interrupt regular mitochondrial function \[[@r21]\]. Changes in mitochondrial genome stability would further cause ATP insufficiency, abnormal cellular function, apoptosis, and ADOA phenotype. Two frameshift, two splice-site, and three nonsense mutations are identified in this study, which are predicted to generate truncated OPA1 proteins or lead to NMD. According to previous reports, the nonsense mutation *OPA1* Q285STOP would cause NMD in a murine model. This partial loss of OPA1 causes mitochondrial respiratory deficiency and a substantial resistance to endoplasmic reticulum stress-induced death \[[@r22],[@r23]\]. Another frameshift mutation, *OPA1* 329_355del, is also found to cause a 50% reduction in the OPA1 protein in a murine model \[[@r24]\]. The OPA1^329_355del^ mice are found to develop visual dysfunction due to RGC loss and an ascending optic neuropathy, while the earliest changes detected in OPA1^Q285STOP^ mice are RGC dendritic changes leading to dysfunctional RGCs. However, it is still unclear why the two murine models display such different phenotypes. The seven heterozygous missense *OPA1* mutations identified in this study are more likely to exert a dominant-negative or deleterious gain-of-function effect \[[@r25]\]. More experiments are still warranted to understand better the pathogenesis of *OPA1* mutations.

Sometimes, clinical diagnoses are challenging in young patients with non-fully manifested phenotypes or due to the clinical heterogeneity with which hereditary retinal diseases manifest. Therefore, genetic tests should be kept be continuously researched to aid unclear clinical diagnoses and to prognosticate the disease. Genetic diagnosis also promises gene therapy or other forms of gene-specific treatments. In conclusion, we revealed eight novel and six recurrent mutations in the *OPA1* gene in 15 Chinese OA families. Our findings expand the *OPA1* mutational spectrum, enrich their phenotype--genotype correlations, provide crucial hints for genetic consultation in these families, and further help with better clinical management.
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